DK0981549T4 - Anvendelse af et inhiberende stof til forbedring af regenereringen af neutroner - Google Patents

Anvendelse af et inhiberende stof til forbedring af regenereringen af neutroner

Info

Publication number
DK0981549T4
DK0981549T4 DK98924307T DK98924307T DK0981549T4 DK 0981549 T4 DK0981549 T4 DK 0981549T4 DK 98924307 T DK98924307 T DK 98924307T DK 98924307 T DK98924307 T DK 98924307T DK 0981549 T4 DK0981549 T4 DK 0981549T4
Authority
DK
Denmark
Prior art keywords
regeneration
neutrons
improve
inhibitory agent
neuronal
Prior art date
Application number
DK98924307T
Other languages
English (en)
Other versions
DK0981549T3 (da
Inventor
H W Prof Dr Mueller
Christine Dr Stichel-Gunkel
Original Assignee
Neuraxo Biopharmaceuticals Gmb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8226794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0981549(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuraxo Biopharmaceuticals Gmb filed Critical Neuraxo Biopharmaceuticals Gmb
Publication of DK0981549T3 publication Critical patent/DK0981549T3/da
Application granted granted Critical
Publication of DK0981549T4 publication Critical patent/DK0981549T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
DK98924307T 1997-05-14 1998-05-13 Anvendelse af et inhiberende stof til forbedring af regenereringen af neutroner DK0981549T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97107846A EP0878480A1 (en) 1997-05-14 1997-05-14 A method for the improvement of neuronal regeneration
PCT/EP1998/002808 WO1998051708A1 (en) 1997-05-14 1998-05-13 A method for the improvement of neuronal regeneration

Publications (2)

Publication Number Publication Date
DK0981549T3 DK0981549T3 (da) 2003-02-10
DK0981549T4 true DK0981549T4 (da) 2007-10-29

Family

ID=8226794

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98924307T DK0981549T4 (da) 1997-05-14 1998-05-13 Anvendelse af et inhiberende stof til forbedring af regenereringen af neutroner

Country Status (8)

Country Link
US (3) US20020115598A1 (da)
EP (2) EP0878480A1 (da)
AT (1) ATE224915T1 (da)
AU (1) AU7654298A (da)
DE (1) DE69808281T3 (da)
DK (1) DK0981549T4 (da)
ES (1) ES2180175T5 (da)
WO (1) WO1998051708A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0878480A1 (en) * 1997-05-14 1998-11-18 H.W. Prof. Dr. Müller A method for the improvement of neuronal regeneration
US6200974B1 (en) 1997-10-24 2001-03-13 Zeneca Limited Phenanthroline derivatives
CN101664408B (zh) * 2001-12-06 2013-05-01 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
HU229475B1 (en) 2001-12-06 2014-01-28 Fibrogen Methods of increasing endogenous erythropoietin (epo)
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
DE10314082A1 (de) * 2003-03-28 2004-10-21 Mcs Micro Carrier Systems Gmbh Biodegradierbares injizierbares Implantat
KR20080044845A (ko) * 2005-09-02 2008-05-21 노이락소 바이오파르마슈티컬즈 게엠베하 철 킬레이트제를 포함하는 약학적 조성물
WO2007048846A1 (de) * 2005-10-27 2007-05-03 Neuraxo Biopharmaceuticals Gmbh Verwendung von eisen chelatisierenden verbindungen, zyklisches adenosinmonophosphat erhöhende verbindungen oder kombinationen davon zur behandlung von axonalen läsionen im zns
EP2000134A1 (en) * 2007-06-06 2008-12-10 Neuraxo Biopharmaceuticals GmbH Use of a substance for the improvement of pns lesions
US9649381B2 (en) 2013-11-06 2017-05-16 Wayne State University Transporter protein-coupled nanodevices for targeted drug delivery
WO2026070815A1 (ja) * 2024-09-26 2026-04-02 利章 大原 神経再生剤及び神経再生方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4214000A (en) † 1978-10-30 1980-07-22 Johnson & Johnson Zinc salt of all-trans-retinoic acid for the treatment of acne
DE3002989A1 (de) 1980-01-29 1981-07-30 Hoechst Ag, 6000 Frankfurt Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels
CA1251729A (en) * 1982-05-19 1989-03-28 Steffen Gay In vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
DE3432094A1 (de) 1984-08-31 1986-03-06 Hoechst Ag, 6230 Frankfurt Ester der pyridin-2,4- und -2,5- dicarbonsaeure als arzneimittel zur inhibierung der prolin- und lysinhydroxylase
US5021404A (en) † 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
WO1993019783A1 (en) * 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
JPH06103773A (ja) † 1992-09-16 1994-04-15 Hitachi Ltd 半導体記憶装置
WO1994017831A1 (en) * 1993-02-11 1994-08-18 Erziehungsdirektion Of The Canton Zurich A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
AU8019694A (en) * 1993-10-15 1995-05-04 Thomas Jefferson University Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
WO1995013291A1 (en) * 1993-11-08 1995-05-18 New York University Neuron-glia cell adhesion molecule, ng-cam, in treatment of nerve damage
US5567609A (en) * 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions
EP0878480A1 (en) * 1997-05-14 1998-11-18 H.W. Prof. Dr. Müller A method for the improvement of neuronal regeneration

Also Published As

Publication number Publication date
WO1998051708A1 (en) 1998-11-19
DE69808281D1 (de) 2002-10-31
DE69808281T2 (de) 2003-01-16
US7208153B2 (en) 2007-04-24
ES2180175T3 (es) 2003-02-01
EP0981549B9 (en) 2008-02-27
EP0878480A1 (en) 1998-11-18
DE69808281T3 (de) 2008-01-24
DK0981549T3 (da) 2003-02-10
ES2180175T5 (es) 2008-02-01
US20070231330A1 (en) 2007-10-04
EP0981549B1 (en) 2002-09-25
EP0981549A1 (en) 2000-03-01
EP0981549B2 (en) 2007-06-27
ATE224915T1 (de) 2002-10-15
US20020115598A1 (en) 2002-08-22
AU7654298A (en) 1998-12-08
US20050118177A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
DE69201400D1 (de) Vorrichtung zum Wiederherstellen von gerissenem Gewebe.
DE69531623D1 (de) Neue benzoxazole
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
ES2145915T3 (es) Derivados estereoquimicos de la wortmannina.
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
NO20002172L (no) FremgangsmÕte for behandling av hyperkolesterolemi med usubstituert polydiallylamin
NO931947D0 (no) Fremgangsmaate for korrosjonshemming
DE69612003D1 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
IL122782A0 (en) Pharmaceutical compositions for treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
FI944523A7 (fi) Papilloomaviruksen inhibitio vastinjuosteoligonukleotidilla
DK0981549T3 (da) Anvendelse af inhiberende stof til forbedring af regenereringen af neutroner
NO880772L (no) Fremgangsmaate til behandling av slam fra avloepsvann.
DK0938326T3 (da) Syntetiske phosphopeptider til behandling af knoglesygdomme
DK0687176T3 (da) Anvendelse af riluzol til behandling af AIDS-relaterede nervesygdomme
ATE425139T1 (de) Benzamidinderivate
FI933902A7 (fi) Substituoidut sykloheksaanijohdannaiset sairauksien hoitamiseksi
ID21534A (id) Konstruksi asam nukleat untuk terapi gen dimana aktifitasnya dipengaruhi oleh inhibitor kinase yang tergantung pada siklin
FI922593L (fi) Inhibition av papillomavirus med çantisenseç-oligonukleotider.
BR9506552A (pt) Método de inibição de integrase retroviral
ID17291A (id) Penghambat matriks metalloprotease oleh asam biaril oksobutirat tersubstitusi
ATE419346T1 (de) Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren
DE69719989D1 (de) Entfernen von schlamm oder mörtel mittels laser
DE69414891D1 (de) System zum Erfassen der Rotorbewegung
ES8707495A1 (es) Un procedimiento para preparar derivados de azetidinona
DK0869785T3 (da) 4-Hydroxycoumarin-3-carboxyamider til behandling af ikke-insulinafhængig diabetes mellitus